Interview with Stephen Turley, Managing Director, Lundbeck Limited (UK)
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
Address: Lundbeck House, Caldecotte Lake Drive, Caldecotte Lake, , Milton Keynes, MK7 8LG, United Kingdom
,United Kingdom
Tel: 0044 1908 649 966
Web: http://uk.lundbeck.com/uk/
Lundbeck is one of Denmark’s most research-intensive enterprises. We employ a total of 1,200 highly-trained specialists in our research and development units. Each year, Lundbeck ploughs back more than 20% of its revenue into research and development of new pharmaceuticals to improve treatment options for the millions of people around the world suffering from neurological disorders.
Lundbeck UK are specialists in psychiatry and pioneers in neurology. We are an international pharmaceutical organisation with a head office based in Milton Keynes, UK and a national field force. The office consists of; Sales & Marketing, Finance & Administration, Human Resources, Medical, and Business Intelligence.
Specialists in psychiatry, pioneers in neurology
As a pharmaceutical manufacturer, Lundbeck is unique in that we focus solely on the treatment of diseases of the central nervous system. Our aim is to be the world leader in the development of pharmaceuticals for psychiatric and neurological disorders, and are pioneers of new treatments and new approaches.
As specialists, our research and development is focused and concentrated. As specialists, we maintain close ties to our customers, establishing new links, building knowledge and developing new programmes. And as specialists, we are closer to the people suffering from psychiatric disorders and the people treating them.
UK Brand Name UK Generic Name
Azilect 1mg Tablets rasagiline
Circadin 2mg prolonged-release tablets melatonin
Cipralex 5mg/10mg/20mg Tablets escitalopram
Cipralex 10mg/ml Drops escitalopram
Cipramil 40mg/ml Drops citalopram
Cipramil 10mg/20mg/40mg Tablets citalopram
Clopixol Acuphase Injection zuclopenthixol
Clopixol Conc Injection zuclopenthixol
Clopixol Injection zuclopenthixol
Clopixol 2mg/10mg/25mg Tablets zuclopenthixol
If we look at Lundbeck globally, the company has been doing very well. Last year was a record year for profits. From a UK perspective, can you provide an overview…
UK pharmaceutical and biotech companies are already finding it increasingly difficult to attract talent from overseas. Additionally, UK firms are looking to poach EMA staff as it heads to Amsterdam…
Belén Garijo, global CEO of Merck Healthcare, speaking this month at the FT Global Pharmaceutical and Biotechnology Conference, ‘Thriving Amid Uncertainty’, in London, underlined the significance of Merck’s new deal…
Hamid Yunis, partner and head of healthcare at the London office of international law firm, McDermott Will & Emery, discusses the potential negative impact of Brexit and the UK leaving…
Among the assorted pharma CEOs and KOLs gathered at the recent Financial Times Pharmaceutical and Biotechnology Conference in London, debate raged on the pros and cons of a pure play strategy, focusing…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, Janssen EMEA’s Jane Griffiths speaks out about patient-centricity, sustainability and the dawning of a new world of healthcare. What’s been keeping you…
In an exclusive interview at the eyeforpharma Barcelona Summit 2016, GSK’s Danie Du Plessis speaks out about patient-centricity and the growing role of medical affairs in the pharma industry. In your…
Can you provide us with an overview of what the UK market represents for the greater Lonza group? Lonza Biologics is a contract manufacturing organisation employing approximately 650 people in…
Having worked in the pharmaceutical industry for the past three decades, what attracted you to Martindale Pharma in October 2010 and what plans do you have for the company? When…
As the head of Eisai’s European operations, how would you assess the relevance of the European market for Eisai’s global operations when compared to the US or emerging markets? Gary…
Following the acquisition of Arrow Generics by Watson in December 2009, what complementarities and synergies were generated from the transaction and where do you stand today with the integration? Since…
As a partner at Apposite since the company was created in 2006, what was the founding vision of the company and what do you consider have been its major milestones…
Apitope’s research and success is based on its High Speed Technology Platform that uses soluble peptides as vehicles to regulate immune responses in patients. What is the history behind this…
See our Cookie Privacy Policy Here
